3SBio Inc. (TRSBF)

Market Cap	3.96B
Revenue (ttm)	1.25B
Net Income (ttm)	286.38M
Shares Out	n/a
EPS (ttm)	0.12
PE Ratio	13.82
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	313
Average Volume	600
Open	0.8279
Previous Close	0.8279
Day's Range	0.8279 - 0.8279
52-Week Range	0.7231 - 0.8279
Beta	0.71
RSI	99.73
Earnings Date	May 9, 2025

About 3SBio

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; Cipterbin, an anti-HER2 monoclonal antibody for the treatment of HER2-positive metastatic breast cancer; TNF, pre-filled aqueous injection solution. It also offers YISAIPU, the receptor fusion tumor necrosis factor inhibitor; Mandi-minoxidil tincture, an OTC external ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 5,577
• Stock Exchange: OTCMKTS
• Ticker Symbol: TRSBF

Financial Performance

In 2024, 3SBio's revenue was 9.11 billion, an increase of 16.53% compared to the previous year's 7.82 billion. Earnings were 2.09 billion, an increase of 34.93%.

Financial numbers in CNY